Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: ...

Last year
R&D

Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Last year
R&D

Ve­rastem On­col­o­gy se­cures col­lab­o­ra­tion with Gen­Fleet Ther­a­peu­tics, po­ten­tial­ly worth up to $600M+

Last year
Deals

FTC paus­es chal­lenge of Am­gen's $28B Hori­zon takeover to con­sid­er set­tle­ment

Last year
Pharma
Law

Ab­cam agrees to $5.7B sale to Dana­her amid founder's push for a board seat

Last year
Deals

Sanofi flies new flag for menin­gi­tis aware­ness, mark­ing one year to the Paris Par­a­lympics with three Team Sanofi ...

Last year
Pharma
Marketing

No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

Last year
R&D

For­mer Schrödinger ex­ec launch­es RA Cap­i­tal-backed start­up for AI drug dis­cov­ery

Last year
Financing
Startups

Up­dat­ed: Bridge­Bio's AT­TR-CM drug bests place­bo in de­tailed PhI­II da­ta, bol­ster­ing plans for NDA

Last year
R&D

Blue­Rock, Bay­er's stem cell group, de­tails glimpses of ef­fi­ca­cy in Parkin­son's dis­ease ther­a­py

Last year
R&D

Rid­ing the wave on lat­est obe­si­ty buy­out; Slack in­ter­view with an­ti-ag­ing re­searcher; Two new IRA law­suits; and more

Last year
Weekly

Neu­mora's big neu­ro­science plans head to­ward the Nas­daq in sec­ond PhI­II biotech IPO pitch in 24 hours

Last year
Financing
Startups

Bax­ter CD­MO Bio­Phar­ma So­lu­tions names Fran­co Ne­gron as CEO ahead of pro­posed sale

Last year
People
Manufacturing

Phar­ma en­ters ‘age of un­cer­tain­ty’ amid chal­lenges from IRA, FTC and patent cliffs

Last year
Pharma

FDA pub­lish­es On­copep­tides’ with­draw­al ap­peal for Swedish biotech’s can­cer drug Pepax­to

Last year
Pharma
FDA+

Am­gen rais­es ‘bad’ cho­les­terol con­cerns in cam­paign with Amer­i­can Heart As­so­ci­a­tion

Last year
Pharma
Marketing

HHS, vac­cine mak­ers prep for first-ever three-vac­cine avail­abil­i­ty with Covid, flu and RSV ahead of peak vi­ral sea­son

Last year
Pharma
Marketing

As­traZeneca dis­putes IRA’s or­phan drug pro­vi­sions in lat­est le­gal chal­lenge to the law

Last year
Pharma
FDA+

Mer­ck kick-starts PhI­II cho­les­terol tri­als for its oral PC­SK9; Bax­ter re­calls 13,000+ vials of chemother­a­py

Last year
News Briefing

Mer­ck and Ei­sai to stop Keytru­da plus Lenvi­ma tri­al in head and neck can­cer af­ter dis­ap­point­ing in­ter­im re­sults

Last year
R&D

Ra­dio­phar­ma­ceu­ti­cals start­up Rayze­Bio sub­mits IPO pitch, fore­shad­ow­ing ex­pect­ed post-La­bor Day bump in biotech ...

Last year
Financing
Startups

Bay­er en­lists Jür­gen Eck­hardt to leap in­to an ad­di­tion­al role; Mi­rati tops list of mul­ti­ple CFO ex­its

Last year
Peer Review

FDA ap­proves San­doz’s na­tal­izum­ab biosim­i­lar, like­ly putting a damper on Bio­gen’s Tysabri sales

Last year
Pharma
FDA+

Once again, Novo's semaglu­tide shows car­dio­vas­cu­lar ben­e­fit, weight loss — this time in adults with heart fail­ure

Last year
R&D
First page Previous page 290291292293294295296 Next page Last page
A service from the Financial Times